![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, March 20, 2006 9:34:03 PM
Diabetes breakthrough may end insulin injections
Updated Fri. Mar. 17 2006 6:23 AM ET
CTV.ca News Staff
Bioengineers at the University of Calgary have successfully grown insulin producing cells in a lab, marking a major breakthrough in diabetes research.
The team of scientists hope to eventually transplant lab grown, insulin producing cells directly into the bodies of patients with Type 1 diabetes.
Type 1 diabetes makes the body unable to produce enough insulin, requiring those suffering from the disease to inject themselves with the hormone.
In theory, the transplant would eliminate the need for daily insulin injections by patients who suffer from the disease.
"This transplant procedure, developed in Edmonton, is the best thing to come in 20 years to treat type one diabetes," Dr. Leo Behie, the professor of chemical engineering in charge of the research project, told CTV Thursday.
The study is significant in the battle against diabetes but there are still many steps to be taken, including clinical trials. The tests that Behie and his team have done in his lab so far are very encouraging.
"In many cases people are off insulin and they have good sugar controls in their blood with no constrains in terms of eating. That is a big deal," said Behie.
The research stems from a sponsored project by New York-based Juvenile Diabetes Research Foundation International (JDRF), that set up 16 researchers from 13 universities around the world.
The researchers are trying to find the cause of the Type 1 disease that affects more than 19-million people worldwide.
"The people who receive the transplants, they have no doubt about it, that they would call this a cure, but I think in this consideration we have to be careful of the word cure. This is more of a treatment that increases hugely your quality of life," Behie said.
Behie and his team developed their conclusions by establishing bioreactor protocols for producing large quantities of pig pancreatic insulin-producing cells.
They hope this will lead to the large-scale production of islet-like structures which contain insulin-producing cells.
Researchers concluded that these cells may be suitable for treating individuals with Type 1 diabetes.
Donna Lillie, of the Canadian Diabetes Association, said the research presents a real possibility for people with Type 1 diabetes that they can get rid of their multiple daily injections.
"Dr. Behie's all-Canadian team has brought us one more step towards potentially securing a large supply of insulin-producing pancreatic cells for transplantation into individuals with Type 1 diabetes," Lillie said.
University of Alberta scientists transplanted cells into Type 1 diabetes sufferers in 2000, freeing some from injections over the last five years.
But the approach they used required pancreas cells from as many as three donor cadavers which created a supply headache. Even with the supply, only 10 per cent were able to stop taking insulin injections.
"There are not nearly enough of these human islets to meet the demand of those who would like to have this transplantation procedure," Behie said.
Behie says his plan to produce cloned cells on a large scale in computer-controlled bioreactors would "get rid of this supply bottleneck."
Behie said his goal is to provide Type 1 diabetes sufferers with a reliable supply of cells that eventually could be given through
Recent INSM News
- Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025 • PR Newswire (US) • 06/27/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 12:00:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:21:15 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 06/07/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 08:23:25 PM
- Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference • PR Newswire (US) • 06/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:00:43 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 08:33:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:46:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:45:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:44:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:43:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:41:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 09:32:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/30/2024 08:15:33 PM
- Insmed to Host Commercial Webinar on June 4, 2024 • PR Newswire (US) • 05/30/2024 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/30/2024 08:02:27 PM
- Insmed Announces Pricing of $650 Million Public Offering of Common Stock • PR Newswire (US) • 05/30/2024 12:00:00 PM
- Insmed Announces Proposed $500 Million Public Offering of Common Stock • PR Newswire (US) • 05/28/2024 10:21:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:51:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:49:20 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:47:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:46:34 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:40:14 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:14:37 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM